Agilus Diagnostics launches Anti-MCV antibody test in collaboration with Sebia to enable early RA diagnosis

New Delhi: Agilus Diagnostics, in collaboration with Sebia, has launched the Anti-MCV (anti–mutated citrullinated vimentin) antibody test in India. Developed by Sebia, this advanced diagnostic tool significantly enhances the early detection of rheumatoid arthritis (RA), especially in patients who test negative for conventional markers such as anti-CCP and rheumatoid factor (RF).

Rheumatoid arthritis (RA), one of the most common autoimmune disorders, affects approximately 0.5–1% of the Indian population, with prevalence expected to rise due to increasing awareness and improved diagnostic capabilities. The Anti-MCV test is now being offered in India by Agilus Diagnostics, expanding access to high-precision diagnostics for patients and clinicians alike.

The test detects autoantibodies against a mutated form of the vimentin protein, commonly found in the synovial fluid of RA patients. It has emerged as a highly sensitive and specific biomarker, particularly valuable in identifying RA in individuals who test negative for traditional markers. Research shows that anti-MCV antibodies may appear even in the absence of anti-CCP and RF, especially in patients exhibiting clinical signs and symptoms of RA. Notably, anti-MCV positivity can precede the clinical onset of RA by up to 24 months, particularly in individuals with a strong family history—making it a powerful tool for early detection and timely intervention.

“At Agilus, we see Anti-MCV filling a crucial diagnostic gap. Studies show that 10–15% of RA cases missed by anti-CCP can be detected through anti-MCV testing. When patients present with persistent symptoms but test negative for both CCP and RF, anti-MCV offers clinicians a valuable next step,” said Dr. Deepak Sanghavi, Senior Vice President – Operations & Chief of the Mumbai Reference Lab, Agilus Diagnostics.

Clinical data also supports the combined use of anti-MCV and anti-CCP to enhance diagnostic accuracy. When used together, these tests can improve sensitivity without compromising specificity—enabling the diagnosis of RA at its earliest stages, when therapeutic intervention is most effective.

Commenting on the collaboration, Dr. Siddhartha Sharma, Head – Clinical & Scientific Affairs, Sebia India, said: “Early detection of RA is critical to prevent irreversible joint damage and improve patient quality of life. We are proud to support Agilus in bringing the Anti-MCV test to clinicians and patients across India.”

This collaboration reflects the shared commitment of Agilus Diagnostics and Sebia to deliver innovative, high-quality diagnostic solutions and advance the standard of care for autoimmune diseases in India.